Tags

Type your tag names separated by a space and hit enter

Topical treatment of atopic dermatitis with St. John's wort cream--a randomized, placebo controlled, double blind half-side comparison.
Phytomedicine. 2003; 10 Suppl 4:31-7.P

Abstract

BACKGROUND

Recent investigations suggest an anti-inflammatory and antibacterial effect of hyperforin, which is a major constituent of Hypericum perforatum L. (Saint John's wort).

OBJECTIVE

In the present half-side comparison study we assessed the efficacy of a cream containing Hypericum: extract standardised to 1.5% hyperforin (verum) in comparison to the corresponding vehicle (placebo) for the treatment of subacute Atopic Dermatitis. The study design was a prospective randomised placebo-controlled double-blind monocentric study.

METHODS

In twenty one patients suffering from mild to moderate Atopic Dermatitis (mean SCORAD 44.5) the treatment with verum or placebo was randomly allocated to the left or right site of the body, respectively. The patients were treated twice daily over a period of four weeks. Eighteen patients completed the study. The severity of the skin lesions on the left and right site was determined by means of a modified SCORAD-index (primary endpoint).

RESULTS

The intensity of the eczematous lesions improved on both sites of treatment. However, the hypericum-cream was significantly superior to the vehicle at all clinical visits (days 7, 14, 28) (p < 0.05). Skin colonisation with Staphylococcus aureus was reduced by both verum and placebo, showing a trend to better antibacterial activity of the hypericum-cream (p = 0.064). Skin tolerance and cosmetic acceptability was good or excellent with both the hypericum-cream and the vehicle (secondary endpoints).

CONCLUSION

Taken together, the present study shows a significant superiority of the hypericum-cream compared to the vehicle in the topical treatment of mild to moderate Atopic Dermatitis. The therapeutic efficacy of the hypericum-cream, however, has to be evaluated in further studies with larger patient cohorts, in comparison to therapeutic standards (i.e. glucocorticoids).

Authors+Show Affiliations

Freiburg University Clinic, Department of Dermatology, Freiburg, Germany. schempp@haut.ukl.uni-freiburg.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12807340

Citation

Schempp, Christoph M., et al. "Topical Treatment of Atopic Dermatitis With St. John's Wort Cream--a Randomized, Placebo Controlled, Double Blind Half-side Comparison." Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, vol. 10 Suppl 4, 2003, pp. 31-7.
Schempp CM, Windeck T, Hezel S, et al. Topical treatment of atopic dermatitis with St. John's wort cream--a randomized, placebo controlled, double blind half-side comparison. Phytomedicine. 2003;10 Suppl 4:31-7.
Schempp, C. M., Windeck, T., Hezel, S., & Simon, J. C. (2003). Topical treatment of atopic dermatitis with St. John's wort cream--a randomized, placebo controlled, double blind half-side comparison. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 10 Suppl 4, 31-7.
Schempp CM, et al. Topical Treatment of Atopic Dermatitis With St. John's Wort Cream--a Randomized, Placebo Controlled, Double Blind Half-side Comparison. Phytomedicine. 2003;10 Suppl 4:31-7. PubMed PMID: 12807340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Topical treatment of atopic dermatitis with St. John's wort cream--a randomized, placebo controlled, double blind half-side comparison. AU - Schempp,Christoph M, AU - Windeck,Timo, AU - Hezel,Svea, AU - Simon,Jan C, PY - 2003/6/17/pubmed PY - 2003/8/15/medline PY - 2003/6/17/entrez SP - 31 EP - 7 JF - Phytomedicine : international journal of phytotherapy and phytopharmacology JO - Phytomedicine VL - 10 Suppl 4 N2 - BACKGROUND: Recent investigations suggest an anti-inflammatory and antibacterial effect of hyperforin, which is a major constituent of Hypericum perforatum L. (Saint John's wort). OBJECTIVE: In the present half-side comparison study we assessed the efficacy of a cream containing Hypericum: extract standardised to 1.5% hyperforin (verum) in comparison to the corresponding vehicle (placebo) for the treatment of subacute Atopic Dermatitis. The study design was a prospective randomised placebo-controlled double-blind monocentric study. METHODS: In twenty one patients suffering from mild to moderate Atopic Dermatitis (mean SCORAD 44.5) the treatment with verum or placebo was randomly allocated to the left or right site of the body, respectively. The patients were treated twice daily over a period of four weeks. Eighteen patients completed the study. The severity of the skin lesions on the left and right site was determined by means of a modified SCORAD-index (primary endpoint). RESULTS: The intensity of the eczematous lesions improved on both sites of treatment. However, the hypericum-cream was significantly superior to the vehicle at all clinical visits (days 7, 14, 28) (p < 0.05). Skin colonisation with Staphylococcus aureus was reduced by both verum and placebo, showing a trend to better antibacterial activity of the hypericum-cream (p = 0.064). Skin tolerance and cosmetic acceptability was good or excellent with both the hypericum-cream and the vehicle (secondary endpoints). CONCLUSION: Taken together, the present study shows a significant superiority of the hypericum-cream compared to the vehicle in the topical treatment of mild to moderate Atopic Dermatitis. The therapeutic efficacy of the hypericum-cream, however, has to be evaluated in further studies with larger patient cohorts, in comparison to therapeutic standards (i.e. glucocorticoids). SN - 0944-7113 UR - https://www.unboundmedicine.com/medline/citation/12807340/Topical_treatment_of_atopic_dermatitis_with_St__John's_wort_cream__a_randomized_placebo_controlled_double_blind_half_side_comparison_ L2 - https://ClinicalTrials.gov/search/term=12807340 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -